NEW YORK--(BUSINESS WIRE)--July 7, 2005--Recent announcements by Wyeth and Pfizer outlining plans to dramatically scale back their sales forces came as no surprise, but they have added a sense of urgency to those troubling questions on the minds of Wall Street analysts, CEOs, and reps in the field:
